Talk to any pharmacist-owner who's been running an independent for twenty-plus years and, sooner or later, they'll say some version of the same thing: it used to be easier. Not easy — pharmacy has never been easy — but easier in a specific way. The dispensary used to carry the business. Now it doesn't, and every owner I talk to already knows it in their gut even if nobody's laid out the shape of the last few decades for them plainly. Worth doing that here, because the shape explains a lot about why things feel the way they feel today.
The golden years: the dispensary as the whole business
There was a stretch — most owners will point somewhere in the decades before the 2010s — when the dispensing side of a pharmacy was, on its own, a genuinely strong business. Margins on generic drugs were healthy. Reimbursement from provincial drug plans and private insurers was generous relative to cost. You could build a viable, even comfortable, independent pharmacy around counting pills and running the counter well. Front-store retail was a nice add-on, not a lifeline. Clinical services barely existed as a line item because they didn't need to.
That era shaped how a lot of owners think about the business, understandably, because it's the era they trained into or bought their pharmacy during. The mental model was: fill the prescriptions, run a tight operation, and the margin takes care of itself. For a long time, it did.
The reforms: where the cushion started coming out
Then, starting in the 2000s and continuing in waves through the 2010s, provinces moved — one after another — to bring down what they paid for generic drugs. The reasoning made sense from the government's side: generics were priced well above what competitive markets would bear, and provincial drug plans were the ones footing the bill. But from the pharmacy side, those reforms landed as repeated cuts to the margin that used to make dispensing profitable on its own. Not a single event — a series of them, spread across different provinces on different timelines, each one trimming a bit more of the cushion.
Alongside the price cuts came pressure on professional and dispensing fees too, and a general tightening of what payers were willing to reimburse. None of it hit every pharmacy the same way — chains absorbed it differently than independents, provinces moved at different speeds — but the direction was consistent enough, for long enough, that it stopped being a rough patch and became the new baseline.
The squeeze: costs went up while margins went down
At the same time the revenue side was tightening, the cost side wasn't cooperating. Rent, wages, insurance, technology — all the ordinary costs of running a storefront kept climbing the way they do for any small business. Big-box pharmacies and grocery-chain pharmacy counters expanded their footprint and could absorb thinner margins at a scale independents couldn't match. Mail-order and online dispensing added another source of competition for the driest part of the business — routine, low-touch refills — which used to be reliable volume.
None of this is about one bad decision or one bad year. It's a slow-moving reform-and-competition environment that kept nudging the same direction for a long time: the dispensary alone got harder to build a whole business around.
Today: the dispensary can't carry it by itself anymore
Which brings us to where most independent owners actually sit right now. The dispensary is still the core of the pharmacy — it's still the thing that brings people through the door and the reason the business exists. But as a standalone profit engine, for most independents, it doesn't do what it used to. The margins that made "just dispense well" a sufficient strategy have been worn down by two decades of reform and competition, and they're not coming back.
We've written about this specific squeeze in more detail — the loans, the reimbursement math, the three financial seasons independents cycle through — in the margin squeeze, if you want the sharper financial picture of where things stand today.
The owners doing well now added what the dispensary can't provide
Here's the part that actually matters going forward, though. Not every independent pharmacy is struggling — some are doing well, and it's not luck or location alone. The ones holding up best tend to share one thing: they stopped treating the dispensary as the entire business and added a clinical service line the dispensary structurally can't provide on its own. Injections, point-of-care testing, medication reviews, travel health consultations — services that get reimbursed or paid for differently than a filled prescription, and that bring in revenue the generic-pricing reforms never touched, because they were never part of that system to begin with.
That's the practical lesson in the rollercoaster, if there is one. The golden years aren't coming back because the policy environment that created them isn't coming back either. But the business doesn't have to shrink to fit the smaller dispensary margin — it just has to stop depending on the dispensary alone to carry it.
Travel medicine is one of the clearer versions of that shift, which is the whole reason the pilot exists — a way to test whether a travel-vaccine consultation service can bring in that kind of revenue without the owner spending a cent finding out.